David Meininger

Company: Link Immunotherapeutics Inc.

Job title: Co-founder & Chief Executive Officer

Seminars:

Panel Discussion: The Relevance & Importance of CRS in Solid Tumors 12:00 pm

Questioning which learnings from the advancements and approvals in liquid tumors are transferable to solid tumors Evaluating if there is a risk of CRS in a solid tumor indication, what can be done to predict and mitigate it Discuss whether CRS will present in a similar way for solid tumor patients compared to liquid tumorsRead more

day: Day Two